Treatment patterns associated with Duloxetine and Venlafaxine use for Major Depressive Disorder

BMC Psychiatry

Volumn 11, Issue , 2011, Pages

  Ye, Wenyu ^a   Zhao, Yang ^a   Robinson, Rebecca L ^a   Swindle, Ralph W ^b  

^a Lilly USA   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIALLERGIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTIMIGRAINE AGENT; ANXIOLYTIC AGENT; ATOMOXETINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DULOXETINE; GASTROINTESTINAL AGENT; HYPNOTIC SEDATIVE AGENT; MONOAMINE OXIDASE INHIBITOR; MUSCLE RELAXANT AGENT; NEUROLEPTIC AGENT; SEROTONIN UPTAKE INHIBITOR; TRANQUILIZER; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE; CYCLOHEXANOL DERIVATIVE; THIOPHENE DERIVATIVE;

ADULT; AGED; ALCOHOLISM; ANXIETY; ANXIETY DISORDER; ARTICLE; ASTHMA; ATTENTION DEFICIT DISORDER; BIPOLAR DISORDER; COMORBIDITY; DEMOGRAPHY; DIABETIC NEUROPATHY; DRUG COST; DRUG USE; DYSLIPIDEMIA; FEMALE; FIBROMYALGIA; GASTROINTESTINAL DISEASE; HEALTH CARE COST; HEALTH INSURANCE; HEART DISEASE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; ORGANIC BRAIN SYNDROME; PAIN; RETROSPECTIVE STUDY; SCHIZOPHRENIA; SLEEP DISORDER; ADOLESCENT; COMPARATIVE STUDY; ECONOMICS; MIDDLE AGED; PSYCHOLOGICAL ASPECT; STATISTICS; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CYCLOHEXANOLS; DEPRESSIVE DISORDER, MAJOR; DRUG COSTS; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; THIOPHENES; TREATMENT OUTCOME;

EID: 79251539252     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/1471-244X-11-19     Document Type: Article

References (26)

1. Stahl SM, Grady MM, Moret C, Briley M. The pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr 2005, 10(9):732-747.
2. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, Norquist G, Howland RH, Lebowitz B, McGrath PJ, Shores-Wilson K, Biggs MM, Balasubramani GK, Fava M, . STAR*D Study Team Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006, 163(1):28-40. 10.1176/appi.ajp.163.1.28, 16390886, STAR*D Study Team.
3. Stahl SM, Entsuah R, Rudolph RL. Comparative efficacy between venlafaxine and SSRIs: a pooled analysis of patients with depression. Biol Psychiatry 2002, 52(12):1166-1174. 10.1016/S0006-3223(02)01425-7, 12488062.
4. Smith D, Dempster C, Glanville J, Freemantle N, Anderson I. Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Br J Psychiatry 2002, 180:396-404. 10.1192/bjp.180.5.396, 11983635.
5. Goldstein DJ, Lu Y, Detke MJ, Wiltse C, Mallinckrodt C, Demitrack MA. Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. J Clin Psychopharmacol 2004, 24(4):389-399. 10.1097/01.jcp.0000132448.65972.d9, 15232330.
6. Thase ME, Pritchett YL, Ossanna MJ, Swindle RW, Xu J, Detke MJ. Efficacy of duloxetine and selective serotonin reuptake inhibitors: comparisons as assessed by remission rates in patients with major depressive disorder. J Clin Psychopharmacol 2007, 27(6):672-676. 10.1097/jcp.0b013e31815a4412, 18004135.
7. Mallinckrodt CH, Prakash A, Houston JP, Swindle RW, Detke MJ, Fava M. Differential antidepressant symptom efficacy: placebo-controlled comparisons of duloxetine and SSRIs (fluoxetine, paroxetine, escitalopram). Neuropsychobiology 2007, 56(2-3):73-85. 10.1159/000111537, 18037817.
8. Baldomero EB, Ubago JG, Cercos CL, Ruiloba JV, Calvo CG, Lopez RP. Venlafaxine extended release versus conventional antidepressants in the remission of depressive disorders after previous antidepressant failure: ARGOS study. Depress Anxiety 2005, 22(2):68-76. 10.1002/da.20080, 16094658.
9. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, Niederehe G, Thase ME, Lavori PW, Lebowitz BD, McGrath PJ, Rosenbaum JF, Sackeim HA, Kupfer DJ, Luther J, Fava M. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006, 163(11):1905-1917. 10.1176/appi.ajp.163.11.1905, 17074942.
10. Hansen RA, Gartlehner G, Lohr KN, Gaynes BN, Carey TS. Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder. Ann Intern Med 2005, 143(6):415-426.
11. Qaseem A, Snow V, Denberg TD, Forciea MA, Owens DK, . for the Clinical Efficacy Assessment Subcommittee of the American College of Physicians Using second-generation antidepressants to treat depressive disorders: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2008, 149(10):725-733. for the Clinical Efficacy Assessment Subcommittee of the American College of Physicians.
12. Papakostas GI, Thase ME, Fava M, Nelson JC, Shelton RC. Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents. Biol Psychiatry 2007, 62(11):1217-1227. 10.1016/j.biopsych.2007.03.027, 17588546.
13. Gartlehner G, Gaynes BN, Hansen RA, Thieda P, DeVeaugh-Geiss A, Krebs EE, Moore CG, Morgan L, Lohr KN. Comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians. Ann Intern Med 2008, 149(10):734-750.
14. Ruhe HG, Huyser J, Swinkels JA, Schene AH. Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systemic review. J Clin Psychiatry 2006, 67(12):1836-1855. 10.4088/JCP.v67n1203, 17194261.
15. Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, Shaw JL, Thompson L, Nelson DL, Hemrick-Luecke SK, Wong DT. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology 2001, 25(6):871-880. 10.1016/S0893-133X(01)00298-6, 11750180.
16. Wong DT, Bymaster FP. Dual serotonin and noradrenaline uptake inhibitor class of anti-depressants: potential for greater efficacy or just hype?. Prog Drug Res 2002, 58:169-222.
17. Cymbalta (duloxetine HCl) delayed-release capsules for oral use. US full prescribing information 2007, Indianapolis, IN: Eli Lilly and Company, Accessed June 15, 2009., http://pi.lilly.com/us/cymbalta-pi.pdf
18. Zimmerman M, Posternak M, Friedman M, Attiullah N, Baymiller S, Boland R, Berlowitz S, Rahman S, Uy K, Singer S. Which factors influence psychiatrists' selection of antidepressants?. Am J Psychiatry 2004, 161(7):1285-1289. 10.1176/appi.ajp.161.7.1285, 15229063.
19. Bauer M, Monz BU, Montejo AL, Quail D, Dantchev N, Demyttenaere K, Garcia-Cebrian A, Grassi L, Perahia DG, Reed C, Tylee A. Prescribing patterns of antidepressants in Europe: results from the Factors Influencing Depression Endpoints Research (FINDER) study. Eur Psychiatry 2008, 23(1):66-73. 10.1016/j.eurpsy.2007.11.001, 18164600.
20. Cassano P, Soares CN, Cohen LS, Lyster AK, Fava M. Sex- and age-related differences in major depressive disorder with comorbid anxiety treated with fluoxetine. Arch Womens Ment Health 2004, 7(3):167-71. 10.1007/s00737-004-0051-y, 15241662.
21. Hochberg YA. Sharper Bonferroni procedure for multiple tests of significance. Biometrika 1988, 75:800-2.
22. Motheral BR, Henderson R, Cox ER. Plan-sponsor savings and member experience with point-of-service prescription step therapy. Am J Manag Care 2004, 10(7 Pt 1):457-464.
23. Dunn JD, Cannon HE, Mitchell MP, Curtiss FR. Utilization and drug cost outcomes of a step-therapy edit for generic antidepressants in an HMO in an integrated health system. J Manag Care Pharm 2006, 12(4):294-302.
24. Marcus SC, Hassan M, Olfson M. Antidepressant switching among adherent patients treated for depression. Psychiatr Serv 2009, 60(5):617-623. 10.1176/appi.ps.60.5.617, 19411348.
25. Perahia DG, Pritchett YL, Kajdasz DK, Bauer M, Jain R, Russell JM, Walker DJ, Spencer KA, Froud DM, Raskin J, Thase ME. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder. J Psychiatr Res 2008, 42:22-34. 10.1016/j.jpsychires.2007.01.008, 17445831.
26. Corey-Lisle P, Nash R, Stang P, Swindle R. Response, partial response, and nonresponse in primary care treatment of depression. Arch Intern Med 2004, 164(11):1197-1204. 10.1001/archinte.164.11.1197, 15197045.